Prescribing information



This page contains information on reimbursement for ILARIS® (canakininab) treatment for autoinflammatory periodic fever syndrome, FMF, HIDS/MKD, and TRAPS in adults aged 2 years and older.


NHS England commissioning

Centres with expertise in adult rheumatology, or adult/paediatric immunology (as appropriate) may prescribe this treatment after discussion with an NHS trust based in England that is a member of the RITA ERN.1

  • Treatment with ILARIS should be managed within specialist centres that have the expertise to manage these complex conditions1
  • These centres are members of the Rare Immunodeficiency, Autoinflammatory and Autoimmune Disease Network (RITA) European Research Network (ERN)1

To find out more about commissioning of ILARIS, click here.


For help completing an Individual Funding Request (IFR), contact us now. 

Contact us

CAPS, cryopyrin-associated periodic syndromes; FMF, familial Mediterranean fever; HIDS, hyperimmunoglobulin D syndrome; MKD, mevalonate kinase deficiency; TRAPS, tumour necrosis factor receptor-associated periodic syndrome.



ILARIS is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:

  • CAPS, including:
    • Muckle-Wells syndrome (MWS)
    • Neonatal-onset multisystem inflammatory disease (NOMID)/chronic infantile neurological, cutaneous, articular syndrome (CINCA)
    • Severe forms of familial cold autoinflammatory syndrome (FCAS)/familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash
  • FMF
    • ILARIS should be given in combination with colchicine, if appropriate.


  1. NHS England. Clinical Commissioning Policy. Canakinumab for treating periodic fever syndromes: TRAPS, HIDS/MKD and FMF (ages 2 years and older). Available at: [Accessed July 2021].
Rate this content: 
No votes yet
UK | November 2021 | 160461

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]